Identification of the catalytic subunit of DNA dependent protein kinase as the product of the mouse scid gene.

P. Jeggo,S. Jackson,G. Taccioli

DOI: https://doi.org/10.1007/978-3-642-50140-1_6

Current topics in microbiology and immunology

Abstract:

What problem does this paper attempt to address?

Physiologic homeostasis after pig-to-human kidney xenotransplantation

Eric Judd,Vineeta Kumar,Paige M Porrett,Kelly A Hyndman,Douglas J Anderson,Maggie E Jones-Carr,Andrew Shunk,Daniel R Epstein,Huma Fatima,Akemi Katsurada,Ryousuke Satou,L Gabriel Navar,Jayme E Locke,Paige M. Porrett,Kelly A. Hyndman,Douglas Anderson,Maggie Jones-Carr,Daniel R. Epstein,L. Gabriel Navar,Jayme E. Locke

DOI: https://doi.org/10.1016/j.kint.2024.01.016

IF: 19.6

2024-01-01

Kidney International

Abstract:Demand for kidney grafts outpaces supply, limiting kidney transplantation as a treatment for kidney failure. Xenotransplantation has the potential to make kidney transplantation available to many more patients with kidney failure, but the ability of xenografts to support human physiologic homeostasis has not been established. A brain-dead adult decedent underwent bilateral native nephrectomies followed by 10 gene-edited (four gene knockouts, six human transgenes) pig-to-human xenotransplantation. Physiologic parameters and laboratory values were measured for seven days in a critical care setting. Data collection aimed to assess homeostasis by measuring components of the renin-angiotensin-aldosterone system, parathyroid hormone signaling, glomerular filtration rate, and markers of salt and water balance. Mean arterial blood pressure was maintained above 60 mmHg throughout. Pig kidneys secreted renin (post-operative day three to seven mean and standard deviation: 47.3 ± 9 pg/mL). Aldosterone and angiotensin II levels were present (post-operative day three to seven, 57.0 ± 8 pg/mL and 5.4 ± 4.3 pg/mL, respectively) despite plasma renin activity under 0.6 ng/mL/hr. Parathyroid hormone levels followed ionized calcium. Urine output down trended from 37 L to 6 L per day with 4.5 L of electrolyte free water loss on post-operative day six. Aquaporin 2 channels were detected in the apical surface of principal cells, supporting pig kidney response to human vasopressin. Serum creatinine down trended to 0.9 mg/dL by day seven. Glomerular filtration rate ranged 90-240 mL/min by creatinine clearance and single-dose inulin clearance. Thus, in a human decedent model, xenotransplantation of 10 gene-edited pig kidneys provided physiologic balance for seven days. Hence, our in-human study paves the way for future clinical study of pig-to-human kidney xenotransplantation in living persons.

urology & nephrology
Radiological features of non-venomous snakebite hand injury.

B. Aceto,K. Sindali,R. Uppal

DOI: https://doi.org/10.1016/j.bjps.2014.12.033

2015-04-01

Abstract:
Chronic dialysis in patients with end‐stage renal disease: Relevance to kidney xenotransplantation

Abhijit Jagdale,David K. C. Cooper,Hayato Iwase,Robert S. Gaston

DOI: https://doi.org/10.1111/xen.12471

2018-11-20

Xenotransplantation

Abstract:<div class="abstract-group"> <section class="article-section article-section__abstract" lang="en" data-lang="en" id="section-1-en"> <h3 class="article-section__header main abstractlang_en main">Abstract</h3> <div class="article-section__content en main"> <p>Renal allotransplantation clearly offers better survival and quality of life for end‐stage renal disease (ESRD) patients than chronic dialysis. The median waiting time for a deceased donor kidney in a suitable ESRD patient is 3.9 years. The initial candidates for pig kidney xenotransplantation will be those with ESRD unlikely to receive an allograft within a reasonable period of time. It is thus reasonable to ascertain whether clinical trials of xenotransplantation might likewise offer superior outcomes. Chronic dialysis in patients with ESRD is associated with poor quality of life, significant morbidity, and relatively high mortality, with only 56% surviving 3 years and 42% at 5 years. However, a significant number of these patients, because of comorbidities, frailty, etc, would not be considered for renal allotransplantation and likely not for xenotransplantation. As genetically engineered pig kidneys have satisfactorily supported life in immunosuppressed nonhuman primates for many months or even more than a year, consideration in carefully selected patients could be given to pig kidney xenotransplantation. We suggest that, in order to give a patient the best possible outcome, the pig kidney could be transplanted pre‐emptively (before dialysis is initiated). If it fails at any stage, the patient would then begin chronic dialysis and continue to await an allograft. The present (limited) evidence is that failure of a pig graft would not be detrimental to a subsequent allograft.</p>

medicine, research & experimental,transplantation
Genetically Modified Porcine Kidneys Have Sufficient Tissue Integrity for Use in Pig-to-Human Xenotransplantation

Douglas J Anderson,Maggie Jones-Carr,Jackson Perry,Vineeta Kumar,Paige Porrett,Jayme E Locke

DOI: https://doi.org/10.1097/SLA.0000000000006380

2024-06-06

Abstract:Objective: We sought to determine if genetically modified porcine kidneys used for xenotransplantation had sufficient tissue integrity to support long term function in a human recipient. Background: Kidney transplantation remains the best available treatment for patients with end-stage kidney disease. However, a shortage of available donor human kidneys prevents many patients from achieving the benefits of transplantation. Xenotransplantation is a potential solution to this shortage. Recent pre-clinical human studies have demonstrated kidneys from genetically modified pig donors can be transplanted without hyperacute rejection and capable of providing creatinine and other solute clearance. It is unknown whether the porcine kidneys would tolerate the relatively higher resting blood pressure in an adult human recipient compared to the pig donor or non-human primate (NHP) recipients used in translational studies. Furthermore, previous experience in NHPs raised concerns about the tissue integrity of the porcine ureter and post-xenotransplant growth of the porcine kidney. Methods: Kidneys recovered from porcine donors with 10 gene edits were transplanted into decedent brain dead recipients who were not eligible for organ donation. Decedents underwent bilateral native nephrectomy prior to transplant and were followed for 3-7 days. Standard induction and maintenance immunosuppression was used as previously reported. Vital signs including blood pressure were recorded frequently. Kidney xenografts were assessed daily, serially biopsied, and were measured at implantation and study completion. Results: Three decedents underwent successful xenotransplantation. Subcapsular hematomas developed requiring incision of the xenograft capsules to prevent Page kidney. Blood pressures were maintained in a physiologic range for adult humans (median arterial pressures (MAP) 108.5mmHg (Interquartile Range (IQR): 97-114mmHg), 74mmHg (IQR: 71-78mmHg), and 95mmHg (IQR: 88-99mmHg. respectively) and no bleeding complications or aneurysm formation was observed. Serial biopsies were taken from the xenografts without apparent loss of tissue integrity, despite the lack of a capsule. Ureteroneocystotomies remained intact without evidence of urine leak. Xenograft growth was observed, but plateaued, in 1 decedent with increased volume of the left and right xenografts by 25% and 26%, respectively, and in the context of human growth hormone levels consistently less <0.1 ng/ml and insulin-like growth factor 1 levels ranging from 34-50 ng/ml. Conclusions: The findings of this study suggest kidneys from 10-gene edited porcine donors have sufficient tissue integrity to tolerate xenotransplantation into a living human recipient. There was no evidence of anastomotic complications and the xenografts tolerated needle biopsy without issue. Xenograft growth occurred but plateaued by study end; further observation and investigation will be required to confirm this finding and elucidate underlying mechanisms.
Cellular dynamics in pig-to-human kidney xenotransplantation

Wanqing Pan,Weimin Zhang,Binghan Zheng,Brendan R Camellato,Jeffrey Stern,Ziyan Lin,Alireza Khodadadi-Jamayran,Jacqueline Kim,Philip Sommer,Karen Khalil,Elaina Weldon,Jiangshan Bai,Yinan Zhu,Peter Meyn,Adriana Heguy,Massimo Mangiola,Adam Griesemer,Brendan J Keating,Robert A Montgomery,Bo Xia,Jef D Boeke

DOI: https://doi.org/10.1016/j.medj.2024.05.003

2024-08-09

Med

Abstract:Background: Xenotransplantation of genetically engineered porcine organs has the potential to address the challenge of organ donor shortage. Two cases of porcine-to-human kidney xenotransplantation were performed, yet the physiological effects on the xenografts and the recipients' immune responses remain largely uncharacterized. Methods: We performed single-cell RNA sequencing (scRNA-seq) and longitudinal RNA-seq analyses of the porcine kidneys to dissect xenotransplantation-associated cellular dynamics and xenograft-recipient interactions. We additionally performed longitudinal scRNA-seq of the peripheral blood mononuclear cells (PBMCs) to detect recipient immune responses across time. Findings: Although no hyperacute rejection signals were detected, scRNA-seq analyses of the xenografts found evidence of endothelial cell and immune response activation, indicating early signs of antibody-mediated rejection. Tracing the cells' species origin, we found human immune cell infiltration in both xenografts. Human transcripts in the longitudinal bulk RNA-seq revealed that human immune cell infiltration and the activation of interferon-gamma-induced chemokine expression occurred by 12 and 48 h post-xenotransplantation, respectively. Concordantly, longitudinal scRNA-seq of PBMCs also revealed two phases of the recipients' immune responses at 12 and 48-53 h. Lastly, we observed global expression signatures of xenotransplantation-associated kidney tissue damage in the xenografts. Surprisingly, we detected a rapid increase of proliferative cells in both xenografts, indicating the activation of the porcine tissue repair program. Conclusions: Longitudinal and single-cell transcriptomic analyses of porcine kidneys and the recipient's PBMCs revealed time-resolved cellular dynamics of xenograft-recipient interactions during xenotransplantation. These cues can be leveraged for designing gene edits and immunosuppression regimens to optimize xenotransplantation outcomes. Funding: This work was supported by NIH RM1HG009491 and DP5OD033430.
Renal xenotransplantation: experimental progress and clinical prospects

Martin Wijkstrom,Hayato Iwase,Wayne Paris,Hidetaka Hara,Mohamed Ezzelarab,David K C Cooper

DOI: https://doi.org/10.1016/j.kint.2016.08.035

Abstract:There are >100,000 patients waiting for kidney transplants in the United States and a vast need worldwide. Xenotransplantation, in the form of the transplantation of kidneys from genetically engineered pigs, offers the possibility of overcoming the chronic shortage of deceased and living human donors. These genetic manipulations can take the form of (i) knockout of pig genes that are responsible for the expression of antigens against which the primate (human or nonhuman primate) has natural "preformed" antibodies that bind and initiate complement-mediated destruction or (ii) the insertion of human transgenes that provide protection against the human complement, coagulation, or inflammatory responses. Between 1989 and 2015, pig kidney graft survival in nonhuman primates increased from 23 days to almost 10 months. There appear to be no clinically significant physiological incompatibilities in renal function between pigs and primates. The organ-source pigs will be housed in a biosecure environment, and thus the risk of transferring an exogenous potentially pathogenic microorganism will be less than that after allotransplantation. Although the risk associated with porcine endogenous retroviruses is considered small, techniques are now available whereby they could potentially be excluded from the pig. The US Food and Drug Administration suggests that xenotransplantation should be restricted to "patients with serious or life-threatening diseases for whom adequately safe and effective alternative therapies are not available." These might include those with (i) a high degree of allosensitization to human leukocyte antigens or (ii) rapid recurrence of primary disease in previous allografts. The potential psychosocial, regulatory, and legal aspects of clinical xenotransplantation are briefly discussed.
Clinical Pig Kidney Xenotransplantation: How Close Are We?

David K. C. Cooper,Hidetaka Hara,Hayato Iwase,Takayuki Yamamoto,Abhijit Jagdale,Vineeta Kumar,Roslyn Bernstein Mannon,Michael J. Hanaway,Douglas J. Anderson,Devin E. Eckhoff

DOI: https://doi.org/10.1681/ASN.2019070651

2019-12-24

Journal of the American Society of Nephrology : JASN

Abstract:Patients with ESKD who would benefit from a kidney transplant face a critical and continuing shortage of kidneys from deceased human donors. As a result, such patients wait a median of 3.9 years to receive a donor kidney, by which time approximately 35% of transplant candidates have died while waiting or have been removed from the waiting list. Those of blood group B or O may experience a significantly longer waiting period. This problem could be resolved if kidneys from genetically engineered pigs offered an alternative with an acceptable clinical outcome. Attempts to accomplish this have followed two major paths: deletion of pig xenoantigens, as well as insertion of "protective" human transgenes to counter the human immune response. Pigs with up to nine genetic manipulations are now available. In nonhuman primates, administering novel agents that block the CD40/CD154 costimulation pathway, such as an anti-CD40 mAb, suppresses the adaptive immune response, leading to pig kidney graft survival of many months without features of rejection (experiments were terminated for infectious complications). In the absence of innate and adaptive immune responses, the transplanted pig kidneys have generally displayed excellent function. A clinical trial is anticipated within 2 years. We suggest that it would be ethical to offer a pig kidney transplant to selected patients who have a life expectancy shorter than the time it would take for them to obtain a kidney from a deceased human donor. In the future, the pigs will also be genetically engineered to control the adaptive immune response, thus enabling exogenous immunosuppressive therapy to be significantly reduced or eliminated.
Current status of pig kidney xenotransplantation

Hayato Iwase,Takaaki Kobayashi

DOI: https://doi.org/10.1016/j.ijsu.2015.07.721

Abstract:Significant progress in life-supporting kidney xenograft survival in nonhuman primates (NHPs) has been associated largely with the increasing availability of pigs with genetic modifications that protect the pig tissues from the primate immune response and/or correct molecular incompatibilities between pig and primate. Blockade of the CD40/CD154 costimulation pathway with anti-CD154 mAb therapy has contributed to prolongation of kidney xenograft survival, although this agent may not be clinically available. An anti-CD40 mAb-based regimen is proving equally successful, but blockade of the CD28/B7 pathway is inadequate. Severe proteinuria were uniformly documented in the early studies of pig kidney xenotransplantation, but whether this resulted from immune injury or from physiological incompatibilities between the species, or both, remained uncertain. Recent experiments suggest it was related to a continuing immune response. Before 2014, the longest survival of a pig kidney graft in a NHP was 90 days, though graft survival >30 days was unusual. Recently this has been extended to >125 days, without features of a consumptive coagulopathy or a protein-losing nephropathy. In conclusion, overcoming the immune, coagulation, and inflammatory responses by the development of precise genetic modifications in donor pigs, along with effective immunosuppressive and anticoagulant/anti-inflammatory therapy is advancing the field towards clinical trials.
Kidney xenotransplantation: Recent progress in preclinical research

Xiao-Hua Yu,Wen-Yi Deng,Hong-Tao Jiang,Tao Li,Yi Wang

DOI: https://doi.org/10.1016/j.cca.2020.11.028

IF: 6.314

2021-03-01

Clinica Chimica Acta

Abstract:<p>Kidney transplantation is the most effective treatment for end-stage renal disease, but is limited by the increasing shortage of deceased and living human donor kidneys. Xenotransplantation using pig organs provides the possibility to resolve the issue of organ supply shortage and is regarded as the next great medical revolution. In the past five years, there have been sequential advances toward the prolongation of life-supporting pig kidney xenograft survival in non-human primates, with the longest survival being 499 days. This progress is due to the growing availability of pigs with multi-layered genetic modifications to overcome the pathobiological barriers and the application of a costimulation blockade-based immunosuppressive regimen. These encouraging results bring the hope to initiate the clinical trials of pig kidney transplantation in the near future. In this review, we summarized the latest advances regarding pig kidney xenotransplantation in preclinical models to provide a basis for future investigation and potential clinical translation.</p>

medical laboratory technology
Consistent survival in consecutive cases of life-supporting porcine kidney xenotransplantation using 10GE source pigs

Daniel Eisenson,Yu Hisadome,Michelle Santillan,Hayato Iwase,WeiLi Chen,Akira Shimizu,Alex Schulick,Du Gu,Armaan Akbar,Alice Zhou,Kristy Koenig,Kasinath Kuravi,Farzana Rahman,Lori Sorrells,Lars Burdorf,Kristina DeSmet,Daniel Warren,Leigh Peterson,Marc Lorber,David Ayares,Andrew Cameron,Kazuhiko Yamada

DOI: https://doi.org/10.1038/s41467-024-47679-6

2024-04-18

Abstract:Xenotransplantation represents a possible solution to the organ shortage crisis and is an imminent clinical reality with long-term xenograft survival in pig-to-nonhuman primate (NHP) heart and kidney large animal models, and short-term success in recent human decedent and clinical studies. However, concerns remain about safe clinical translation of these results, given the inconsistency in published survival as well as key differences between preclinical procurement and immunosuppression and clinical standards-of-care. Notably, no studies of solid organ pig-to-NHP transplantation have achieved xenograft survival longer than one month without CD40/CD154 costimulatory blockade, which is not currently an FDA-approved immunosuppression strategy. We now present consistent survival in consecutive cases of pig-to-NHP kidney xenotransplantation, including long-term survival after >3 hours of xenograft cold preservation time as well as long-term survival using FDA-approved immunosuppression. These data provide critical supporting evidence for the safety and feasibility of clinical kidney xenotransplantation. Moreover, long-term survival without CD40/CD154 costimulatory blockade may provide important insights for immunosuppression regimens to be considered for first-in-human clinical trials.
Xenotransplantation: Where Are We with Potential Kidney Recipients? Recent Progress and Potential Future Clinical Trials

Kazuhiko Yamada,Jigesh A Shah,Tatsu Tanabe,Miguel A Lanaspa,Richard J Johnson

DOI: https://doi.org/10.1007/s40472-017-0149-6

Abstract:Purpose: Inter-species transplantation, xenotransplantation, is becoming a realistic strategy to solve the organ shortage crisis. Here we focus on seminal publications that have driven research in xenotransplantation, as well as recently published literature and future endeavors. Recent findings: Advances in gene editing technology have allowed for the efficient production of multi-transgenic porcine donors leading improved xenograft survival in baboons, up to 2-years following heterotopic heart xenotransplantation and from weeks to several months following life-supporting kidney xenotransplanation. As technology evolves, additional challenges have arisen, including the development of proteinuria, early graft loss associated with porcine CMV, disparities in organ growth between donors and recipients as well as high-dose continuous immunosuppression requirements. To address these issues, our laboratory developed a tolerance-inducing protocol which has allowed for >6 months survival of a life-supporting kidney with further approaches currently underway to address the challenges mentioned above. Summary: Our recent findings, reviewed in this article, led us to develop methods to overcome obstacles, which, in conjunction with the work of others, are promising for future clinical applications of xenotransplantation.
Pig kidney xenotransplantation: Progress toward clinical trials

David K. C. Cooper,Hidetaka Hara,Hayato Iwase,Takayuki Yamamoto,Zheng‐Yu Wang,Abhijit Jagdale,Mohamed H. Bikhet,Huy Q. Nguyen,Jeremy B. Foote,Wayne D. Paris,David Ayares,Vineeta Kumar,Douglas J. Anderson,Jayme E. Locke,Devin E. Eckhoff

DOI: https://doi.org/10.1111/ctr.14139

2020-11-19

Clinical Transplantation

Abstract:<p>Pig organ xenotransplantation offers a solution to the shortage of deceased human organs for transplantation. The pathobiological response to a pig xenograft is complex, involving antibody, complement, coagulation, inflammatory, and cellular responses. To overcome these barriers, genetic manipulation of the organ‐source pigs has largely been directed to two major aims – (i) deletion of expression of the known carbohydrate xenoantigens against which humans have natural (preformed) antibodies, and (ii) transgenic expression of human protective proteins, e.g., complement‐ and coagulation‐regulatory proteins. Conventional (FDA‐approved) immunosuppressive therapy is unsuccessful in preventing an adaptive immune response to pig cells, but blockade of the CD40:CD154 costimulation pathway is successful. Survival of genetically‐engineered pig kidneys in immunosuppressed nonhuman primates can now be measured in months. Non‐immunological aspects, e.g., pig renal function, a hypovolemia syndrome, and rapid growth of the pig kidney after transplantation, are briefly discussed. We suggest that patients on the wait‐list for a deceased human kidney graft who are unlikely to receive one due to long waiting times are those for whom kidney xenotransplantation might first be considered. The potential risk of infection, public attitudes to xenotransplantation, and ethical, regulatory, and financial aspects are briefly addressed.</p>

surgery,transplantation
Design and testing of a humanized porcine donor for xenotransplantation

Ranjith P. Anand,Jacob V. Layer,David Heja,Takayuki Hirose,Grace Lassiter,Daniel J. Firl,Violette B. Paragas,Adam Akkad,Sagar Chhangawala,Robert B. Colvin,Russell J. Ernst,Nicholas Esch,Kristen Getchell,Alexandra K. Griffin,Xiaoyun Guo,Katherine C. Hall,Paula Hamilton,Lokesh A. Kalekar,Yinan Kan,Ahmad Karadagi,Feng Li,Susan C. Low,Rudy Matheson,Claudia Nehring,Ryo Otsuka,Matthew Pandelakis,Robert A. Policastro,Rebecca Pols,Luis Queiroz,Ivy A. Rosales,William T. Serkin,Kathryn Stiede,Toshihide Tomosugi,Yongqiang Xue,Gabriel E. Zentner,David Angeles-Albores,J. Chris Chao,Juliet N. Crabtree,Sierra Harken,Nicole Hinkle,Tania Lemos,Mailin Li,Lorena Pantano,Denise Stevens,Omar D. Subedar,Xiaoqing Tan,Shiyi Yin,Imran J. Anwar,David Aufhauser,Saverio Capuano,Dixon B. Kaufman,Stuart J. Knechtle,Jean Kwun,Dhanansayan Shanmuganayagam,James F. Markmann,George M. Church,Mike Curtis,Tatsuo Kawai,Michele E. Youd,Wenning Qin

DOI: https://doi.org/10.1038/s41586-023-06594-4

IF: 64.8

2023-10-12

Nature

Abstract:Recent human decedent model studies 1,2 and compassionate xenograft use 3 have explored the promise of porcine organs for human transplantation. To proceed to human studies, a clinically ready porcine donor must be engineered and its xenograft successfully tested in nonhuman primates. Here we describe the design, creation and long-term life-supporting function of kidney grafts from a genetically engineered porcine donor transplanted into a cynomolgus monkey model. The porcine donor was engineered to carry 69 genomic edits, eliminating glycan antigens, overexpressing human transgenes and inactivating porcine endogenous retroviruses. In vitro functional analyses showed that the edited kidney endothelial cells modulated inflammation to an extent that was indistinguishable from that of human endothelial cells, suggesting that these edited cells acquired a high level of human immune compatibility. When transplanted into cynomolgus monkeys, the kidneys with three glycan antigen knockouts alone experienced poor graft survival, whereas those with glycan antigen knockouts and human transgene expression demonstrated significantly longer survival time, suggesting the benefit of human transgene expression in vivo. These results show that preclinical studies of renal xenotransplantation could be successfully conducted in nonhuman primates and bring us closer to clinical trials of genetically engineered porcine renal grafts.

multidisciplinary sciences
Characterizing coagulation responses in humans and nonhuman primates following kidney xenotransplantation—A narrative review

Ali Zidan,Adham H. El‐Sherbini,Abdelrahman Noureldin,David K. C. Cooper,Maha Othman

DOI: https://doi.org/10.1002/ajh.27506

IF: 13.265

2024-10-16

American Journal of Hematology

Abstract:The recent report of the first pig kidney transplant in a living human brings hope to thousands of people with end‐stage kidney failure. The scientific community views this early success with caution as kidney xenotransplantation exhibits many challenges and barriers. One of these is coagulation dysregulation. This includes (i) pig von Willebrand Factor (vWF) interaction with human platelets, which can induce abnormal clotting responses, heightening the risk of graft failure, (ii) the inefficiency of pig thrombomodulin in activating human protein C, which emphasizes the species‐specific variations that aggravate coagulation challenges, and (iii) the development of thrombotic microangiopathy in the pig grafts and the occurrence of systemic consumptive coagulopathy in the recipients. Indeed, coagulation dysregulation largely results from differences in endothelial cell response and incompatibilities between pig and human coagulation–anticoagulation pathways. These barriers can be resolved by modifications to pig vWF and the expression of human thrombomodulin and endothelial protein C receptors in pig cells, serving as strategic interventions to align the coagulation systems of the two species more closely. These coagulation challenges have clinical implications in how they affect graft survival and patient outcome. Genetic engineering of the organ‐source pig and the administration of various drugs have assisted in correcting this coagulation dysregulation. Hence, comprehending and controlling coagulation dysregulation is crucial for progress in xenotransplantation as a viable option for treating patients with terminal kidney disease.

hematology
Spatiotemporal immune atlas of a clinical-grade gene-edited pig-to-human kidney xenotransplant

Matthew D. Cheung,Rebecca Asiimwe,Elise N. Erman,Christopher F. Fucile,Shanrun Liu,Chiao-Wang Sun,Vidya Sagar Hanumanthu,Harish C. Pal,Emma D. Wright,Gelare Ghajar-Rahimi,Daniel Epstein,Babak J. Orandi,Vineeta Kumar,Douglas J. Anderson,Morgan E. Greene,Markayla Bell,Stefani Yates,Kyle H. Moore,Jennifer LaFontaine,John T. Killian,Gavin Baker,Jackson Perry,Zayd Khan,Rhiannon Reed,Shawn C. Little,Alexander F. Rosenberg,James F. George,Jayme E. Locke,Paige M. Porrett

DOI: https://doi.org/10.1038/s41467-024-47454-7

IF: 16.6

2024-04-11

Nature Communications

Abstract:Abstract Pig-to-human xenotransplantation is rapidly approaching the clinical arena; however, it is unclear which immunomodulatory regimens will effectively control human immune responses to pig xenografts. Here, we transplant a gene-edited pig kidney into a brain-dead human recipient on pharmacologic immunosuppression and study the human immune response to the xenograft using spatial transcriptomics and single-cell RNA sequencing. Human immune cells are uncommon in the porcine kidney cortex early after xenotransplantation and consist of primarily myeloid cells. Both the porcine resident macrophages and human infiltrating macrophages express genes consistent with an alternatively activated, anti-inflammatory phenotype. No significant infiltration of human B or T cells into the porcine kidney xenograft is detectable. Altogether, these findings provide proof of concept that conventional pharmacologic immunosuppression may be able to restrict infiltration of human immune cells into the xenograft early after compatible pig-to-human kidney xenotransplantation.

multidisciplinary sciences
Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens

Takayuki Yamamoto,Hidetaka Hara,Jeremy Foote,Liaoran Wang,Qi Li,Edwin C Klein,Hendrik Jan Schuurman,Hongmin Zhou,Juan Li,A Joseph Tector,Zhongqiang Zhang,Mohamed Ezzelarab,Ray Lovingood,David Ayares,Devin E Eckhoff,David K C Cooper,Hayato Iwase,Edwin C. Klein,A. Joseph Tector,Devin E. Eckhoff,David K.C. Cooper

DOI: https://doi.org/10.1097/tp.0000000000002796

2019-10-01

Transplantation

Abstract:BACKGROUND: The aims of this study were to evaluate the efficacy of US Food and Drug Administration-approved drugs in genetically engineered pig-to-baboon kidney xenotransplantation and compare the results with those using an anti-CD40 monoclonal antibody (mAb)-based regimen.METHODS: Ten life-supporting kidney transplants were carried out in baboons using α1,3-galactosyltransferase gene-knockout/CD46 pigs with various other genetic manipulations aimed at controlling coagulation dysregulation. Eight transplants resulted in informative data. Immunosuppressive therapy consisted of induction with antithymocyte globulin and anti-CD20mAb, and maintenance based on either (1) CTLA4-Ig and/or tacrolimus (+rapamycin or mycophenolate mofetil) (GroupA [US Food and Drug Administration-approved regimens], n = 4) or (2) anti-CD40mAb + rapamycin (GroupB, n = 4). All baboons received corticosteroids, interleukin-6R blockade, and tumor necrosis factor-α blockade. Baboons were followed by clinical and laboratory monitoring of kidney function, coagulation, and immune parameters. At euthanasia, morphological and immunohistochemical studies were performed on the kidney grafts.RESULTS: The median survival in GroupB was 186 days (range 90-260), which was significantly longer than in GroupA; median 14 days (range 12-32) (P < 0.01). Only GroupA baboons developed consumptive coagulopathy and the histopathological features of thrombotic microangiopathic glomerulopathy and interstitial arterial vasculitis.CONCLUSIONS: Recognizing that the pig donors in each group differed in some genetic modifications, these data indicate that maintenance immunosuppression including anti-CD40mAb may be important to prevent pig kidney graft failure.

immunology,surgery,transplantation
[Effect of cardiac glycosides on calcium, sodium, water and glucose transport in the isolated small intestine].

W. Forth,W. Rummel

Abstract:
Prolonged xenokidney graft survival in sensitized NHP recipients by expression of multiple human transgenes in a triple knockout pig

Miriam Manook,Danae Olaso,Imran Anwar,Isabel DeLaura,Janghoon Yoon,Yeeun Bae,Andrew Barbas,Brian Shaw,Dimitrios Moris,Mingqing Song,Alton B. Farris,Kathryn Stiede,Michele Youd,Stuart Knechtle,Jean Kwun

DOI: https://doi.org/10.1126/scitranslmed.adk6152

IF: 17.1

2024-06-14

Science Translational Medicine

Abstract:Genetic modification of porcine donors, combined with optimized immunosuppression, has been shown to improve outcomes of experimental xenotransplant. However, little is known about outcomes in sensitized recipients, a population that could potentially benefit the most from the clinical implementation of xenotransplantation. Here, five highly allosensitized rhesus macaques received a porcine kidney from GGTA1 (α1,3-galactosyltransferase) knockout pigs expressing the human CD55 transgene (1KO.1TG) and were maintained on an anti-CD154 monoclonal antibody (mAb)–based immunosuppressive regimen. These recipients developed de novo xenoreactive antibodies and experienced xenograft rejection with evidence of thrombotic microangiopathy and antibody-mediated rejection (AMR). In comparison, three highly allosensitized rhesus macaques receiving a kidney from GGTA1 , CMAH (cytidine monophospho- N -acetylneuraminic acid hydroxylase), and b4GNT2 / b4GALNT2 (β-1,4- N -acetyl-galactosaminyltransferase 2) knockout pigs expressing seven human transgenes including human CD46 , CD55 , CD47 , THBD (thrombomodulin), PROCR (protein C receptor), TNFAIP3 (tumor necrosis factor–α–induced protein 3), and HMOX1 (heme oxygenase 1) (3KO.7TG) experienced significantly prolonged graft survival and reduced AMR, associated with dampened post-transplant humoral responses, early monocyte and neutrophil activation, and T cell repopulation. After withdrawal of all immunosuppression, recipients who received kidneys from 3KO.7TG pigs rejected the xenografts via AMR. These data suggest that allosensitized recipients may be suitable candidates for xenografts from genetically modified porcine donors and could benefit from an optimized immunosuppression regimen designed to target the post-transplant humoral response, thereby avoiding AMR.

cell biology,medicine, research & experimental
Epidemiology of Reiter's syndrome in Rochester, Minnesota: 1950-1980.

C. Michet,E. Machado,D. Ballard,C. H. Mckenna

DOI: https://doi.org/10.1002/ART.1780310316

1988-03-01

Arthritis & Rheumatism

Abstract:The incidence of Reiter's syndrome in a predominantly white, community-based population is reported. The age-adjusted annual incidence rate for males younger than age 50 was 3.5 per 100,000. No female cases were identified. Over time, a greater proportion of cases have been identified among younger males. In 63% of the patients, either a prolonged or relapsing disease course occurred.

Identification of the catalytic subunit of DNA dependent protein kinase as the product of the mouse scid gene.

Physiologic homeostasis after pig-to-human kidney xenotransplantation

Radiological features of non-venomous snakebite hand injury.

Chronic dialysis in patients with end‐stage renal disease: Relevance to kidney xenotransplantation

Genetically Modified Porcine Kidneys Have Sufficient Tissue Integrity for Use in Pig-to-Human Xenotransplantation

Cellular dynamics in pig-to-human kidney xenotransplantation

Renal xenotransplantation: experimental progress and clinical prospects

Clinical Pig Kidney Xenotransplantation: How Close Are We?

Current status of pig kidney xenotransplantation

Kidney xenotransplantation: Recent progress in preclinical research

Consistent survival in consecutive cases of life-supporting porcine kidney xenotransplantation using 10GE source pigs

Xenotransplantation: Where Are We with Potential Kidney Recipients? Recent Progress and Potential Future Clinical Trials

Pig kidney xenotransplantation: Progress toward clinical trials

Design and testing of a humanized porcine donor for xenotransplantation

Characterizing coagulation responses in humans and nonhuman primates following kidney xenotransplantation—A narrative review

Spatiotemporal immune atlas of a clinical-grade gene-edited pig-to-human kidney xenotransplant

Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens

[Effect of cardiac glycosides on calcium, sodium, water and glucose transport in the isolated small intestine].

Prolonged xenokidney graft survival in sensitized NHP recipients by expression of multiple human transgenes in a triple knockout pig

Epidemiology of Reiter's syndrome in Rochester, Minnesota: 1950-1980.